Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 14, Issue 10, 2012, Pages 944-950

  Heise, T ^a   Nosek, L ^a   Bottcher S G ^b   Hastrup, H ^b   Haahr, H ^b  

^a Profil Institute for Metabolic Research   (Germany)

^b NOVO NORDISK A S   (Denmark)

Author keywords

Insulin analogues; Pharmacodynamics; Randomized trial; Type 2 diabetes

Indexed keywords

C PEPTIDE; CREATININE; GLUCOSE; HEMOGLOBIN A1C; IDEG; INSULIN DEGLUDEC; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GLUCOSE INFUSION; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INJECTION SITE REACTION; MALE; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; TREATMENT DURATION;

EID: 84865972844     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2012.01638.x     Document Type: Article

References (21)

1. Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab 2007; 9: 648-659.
2. Jonassen I, Havelund S, Ribel U et al. Insulin degludec is a new generation ultra-long acting basal insulin with a unique mechanism of protraction based on multi-hexamer formation. Diabetes 2010; 59(Suppl. 1): A11.
3. Kurtzhals P, Heise T, Strauss HM et al. Multi-hexamer formation is the underlying basis for the ultra-long glucose-lowering effect of insulin degludec. Diabetologia 2011; 54: S426.
4. Lepore M, Pampanelli S, Fanelli C et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000; 49: 2142-2148.
5. Rowland M, Tozer TN. Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications. Philadelphia, PA: Wolters Kluwer Health/Lippincott William & Wilkins, 2011.
6. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203.
7. Bott S, Tusek C, Jacobsen LV et al. Insulin detemir under steady-state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with Type 1 diabetes. Diabetic Med 2006; 23: 522-528.
8. Heise T, Nosek L, Ronn BB et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004; 53: 1614-1620.
9. Porcellati F, Rossetti P, Ricci NB et al. Pharmacokinetics and pharmacodynamics of the long-acting insulin analog glargine after 1 week of use compared with its first administration in subjects with type 1 diabetes. Diabetes Care 2007; 30: 1261-1263.
10. Heise T, Hermanski L, Nosek L, Feldmann A, Rasmussen S, Haahr H. Insulin degludec: four times lower pharmacodynamics variability than insulin glargine under steady state conditions in type 1 diabetes. Diabetes Obes Metab 2012 [Epub ahead of print].
11. Atkin SL, Bain SC, Gough S et al. Insulin degludec does not compromise efficacy or safety when given in a flexible once-daily dosing regimen compared to insulin glargine once daily at the same time each day in type 2 diabetes. Diabetologia 2011; 54: S53.
12. Zinman B, Fulcher G, Rao PV et al. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. Lancet 2011; 377: 924-931.
13. Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab 2007; 9: 290-299.
14. Wang Z, Hedrington MS, Gogitidze JN et al. Dose-response effects of insulin glargine in type 2 diabetes. Diabetes Care 2010; 33: 1555-1560.
15. Lantus-scientific discussion, 2003. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000284/WC500036075.pdf. Accessed 28 November 2011.
16. Heller S, Buse J, Fisher M et al. Insulin degludec, an ultra-long-acting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012; 379: 1489-1497.
17. Garber AJ, King AB, Del Prato S et al. Insulin degludec, an ultra-long-acting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012; 379: 1498-1507.
18. Ashwell SG, Gebbie J, Home PD. Optimal timing of injection of once-daily insulin glargine in people with Type 1 diabetes using insulin lispro at meal-times. Diabet Med 2006; 23: 46-52.
19. Swinnen SG, Simon AC, Holleman F, Hoekstra JB, DeVries JH. Insulin detemir versus insulin glargine for type 2 diabetes mellitus. Cochrane Database Syst Rev 2011: CD006383.
20. DeVries JH, Lindholm A, Jacobsen JL, Heine RJ, Home PD. A randomized trial of insulin aspart with intensified basal NPH insulin supplementation in people with Type 1 diabetes. Diabet Med 2003; 20: 312-318.
21. Del Sindalco P, Ciofetta M, Lalli C et al. Use of the short-acting insulin analogue lispro in intensive treatment of type 1 diabetes mellitus: importance of appropriate replacement of basal insulin and time-interval injection-meal. Diabet Med 1998; 15: 592-600.